Biophan bei 0,50 Euro und dann das !
 |  manager01 | 11.08.04 16:09   |
| Pelzmonster macht? Das hier nur Genossen rumrennen die nischt produktives bringen! Ich erinnere mich an Zeiten da wurde hier eine scheiße vom Himmel geprädigt und Kurspotentiale um weitere 150% gepusht und trompetet, da hab ich mich mit meinen Börsenkumpels schon damals über diese Leute weggelacht und wie man sieht hat der Manager recht gehabt und die Luschen haben inzwischen den Kopf gesengt und haben sich als Börsenanalphabeten geoutet und zurückgezogen. Es zeigt mir das sich die richtigen Profis(die wirklichen, nicht die handelsüblichen Schaumschläger die lieber Sandburgen bauen sollten) sich nicht die Bohne für diese Aktie interessieren. Ich kann nur sagen: Geil! Biophan=Bruchladen ...und Totalverluste für alle unbelehrbaren! | AG-Filter: BIOPHAN TECHS Übersicht Kurse Chart News Forum Performance seit Posting Boardmail schreiben Benutzer markieren  Benutzer ignorieren Hinweis an ARIVA.DE-Team |
Nicht alle Ami-Aktien sind schlecht!
xpfuture
nun habe ich 60 % realisiert, nicht das erste mal mit BIPH - und über die Steuer kann ich nur lachen bei den Prozenten !
wir sehen uns !
Gruß
leo
ich habe halt mal wieder 60 % realisiert -------- und das ist kein Scherz !
alles Gute !
Gruß
leo
ROCHESTER, NY, Sep. 27, 2004 (MARKET WIRE via COMTEX) -- AXcess News
(www.axcessnews.com) released a story covering the recent move by the FDA to
speed development of MRI-compatible implants following Biophan Technologies,
Inc. (OTC BB: BIPH) announcement that it filed 12 more MRI-related patents
Friday.
That news fell on the heels of a story last week that cited the FDA's plans to
speed development of MRI-compatible implants.
The FDA has funded $21 million for its scientists to test ways of improving MRI
safety for patients while manufacturers are working to develop new technologies
that can expand MRI capabilities and break the barrier of entrance into market.
Medical device stocks ended the week up, led by Boston Scientific Corp. after
inking a deal with specialty drug maker Angiotech Pharmaceuticals Inc. for the
exclusive rights to use the cancer drug paclitaxel on its drug-coated coronary
stents. Boston Scientific is also working with Biophan to develop its MRI
technologies and could step up its involvement following Biophan's latest round
of patent filings.
According to Biophan the patents filed Friday, "outline new advances in the use
of Magnetic Resonance Imaging (MRI), as well as nanotechnology coatings,
biothermal batteries and opto-electric controls for implanted medical devices."
Biophan's President Michael Weiner called the patents "milestones in broadening
Biophan's intellectual property portfolio."
Nine of the twelve newly filed patents are related to the Company's
'anti-antenna' geometries for stent designs, enabling the manufacture of stents
that do not interfere with MRI imaging of the stent interior.
Boston Scientific's recent attention to stents [coating stents with paclitaxel]
puts a different perspective on Weiner's comments when he called the patent
filings "milestones."
The company had not comment on their development work with Boston Scientific
following their press release on the patent filings Friday.
Johnson & Johnson Inc. said its Cordis devices unit plans to present data at a
heart conference next week showing head-to-head real world data comparing safety
and efficacy rates of its Cypher coronary stent, coated with the
immunosuppressive drug Sirolimus, with Taxus data.
Biophan Technologies, Inc. (OTC BB: BIPH) closed up 5 cents, or 6.5%, to end the
week's session at $.81. Boston Scientific closed up 49 cents at $38.28 and
Johnson & Johnson closed down 1 cent at $56.55, but gained 10 cents in the
extended session.
More news on the investment horizon for the medical device sector can be found
at AXcess News: http://www.axcessnews.com. This is an excerpt from the complete
story. More companies were covered in that news in the Health section of AXcess
News.
About AXcess News:
Dubbed the "Yahoo! of small cap business news" by Gordon Borrell, one of
America's leading media and research gurus, AXcess News is fast becoming a known
commodity for both the serious investor and people in general looking for
informed articles and insightful columns. http://www.axcessnews.com
Media Contact:
Eric Stevenson
Of AXcess News
+1-775-972-7128
eric@axcessnews.com
SOURCE: AXcess News
DALLAS, Sep 27, 2004 (PRIMEZONE via COMTEX) -- TalkingStocks.com has issued an
`Attractive' rating for Biophan Technologies (OTCBB: BIPH), a cutting-edge
developer of next-generation biotechnologies.
In the report, Jeff Bishop, Senior Investment Analyst for TalkingStocks.com,
discusses at length his outlook for the company. Mr. Bishop shares this comment
about Biophan, "We believe that in the coming months, the market will gradually
digest the company's news and see the true value of its products. Investors who
are willing to take the time to understand this remarkable company and invest in
it early should see significant returns as the company gains favor on Wall
Street." He later adds, "The company's strategy of using joint ventures, such as
that with Boston Scientific (NYSE:BSX), will most likely create win-win
opportunities for both firms."
The report can be viewed in its entirety on TalkingStocks.com, or by clicking
the link below:
http://www.talkingstocks.com/reports/BIPH_092704.php
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make
biomedical devices safe and compatible with magnetic resonance imaging (MRI)
equipment. The Company develops enabling technologies for implanted medical
systems such as pacemakers, and interventional surgical devices such as
catheters and guidewires, as well as stents and other implants that can be
safely and effectively imaged under MRI. The technology is also being used to
create enhanced MRI contrast agents, and has expanded to include other
applications, such as drug delivery and power systems derived from body heat.
Four Biophan product lines include advances in nanotechnology and thin film
coatings. Committed to growth through innovation and developmental leadership,
Biophan and its licensors have 20 issued U.S. patents and 72 patents pending, in
areas including nanotechnology (nanomagnetic particle coatings), radio frequency
filters, polymer composites, thermoelectric materials for batteries generating
power from body heat, and photonics. Biophan has joint development arrangements
with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology.
Biophan's goal is to make all biomedical devices capable of safely and
successfully working with MRI, and delivering other technologies which will
improve quality of life. For more information, please visit www.biophan.com.
About TalkingStocks.com
TalkingStocks.com is a leading Internet stock investment web site providing
coverage and analysis of many up-and-coming firms. TalkingStocks.com is
associated with Stockguru.com. Both offer profiles and interviews with key
executives from publicly traded companies. For more information on
TalkingStocks.com, contact John Pentony, 972-731-8621, Publisher@stockguru.com.
Disclosure: TalkingStocks.com has been compensated $3000 for coverage.
Cautionary Language
Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein. Further, the
Company operates in industries where securities values may be volatile and may
be influenced by regulatory and other factors beyond the Company's control.
Other important factors that the Company believes might cause such differences
are discussed in the risk factors detailed in the Company's 10-KSB and its
quarterly reports on Form 10-QSB both as filed with the Securities and Exchange
Commission, which include the Company's cash flow difficulties, dependence on
significant customers, and rapid development of technology, among other risks.
In assessing forward-looking statements contained herein, readers are urged to
carefully read all cautionary statements contained in the Company's filings with
the Securities and Exchange Commission.
Web Alert: Biophan, Giant Motorsports and WorldWater to Present in Trilogy Capital's Emerging Growth Microcap Forum Webcast 12:00 noon ET
Tuesday November 30, 10:34 am ET
LOS ANGELES--(BUSINESS WIRE)--Nov. 30, 2004--Top executives and spokesman from the emerging growth microcap companies Biophan Technologies Inc. (OTCBB:BIPH - News), Giant Motorsports Inc. (OTCBB:GMOS - News) and WorldWater & Power Corp. (OTCBB:WWAT - News) will present strategic plans and other information about their companies and stock in an online webcast open to all interested investors, scheduled to start at 12 noon ET, today.
The webcast will last approximately 20 minutes. To view the conference, register online as explained below. Conference and webcast information is as follows: What: Biophan Technologies, Giant Motorsports and WorldWater & Power Corp., will present at Trilogy Capital's Emerging Growth Microcap Forum. This live over-the-Internet video presentation employs a fast-moving, highly informative format. It features on-camera presentations by CEOs and company presenters with side-by-side informational slides.Who: Conference Moderator: A.J. Cervantes, President -- Trilogy Capital Partners, Inc.When: Today, Nov. 30, 2004, at 12 pm ETWhere: Please register at www.trilogy-capital.com. Simply log on and you will be able to view the webcast.Cost: The conference is free of charge and open to all interested investors.Archive: If you are unable to view the initial webcast, the Forum will be archived for replay at http://www.trilogy-capital.com.Contact: Paul Karon at 800-342-1467 or paul@trilogy-capital.com.
About the Companies:
Biophan Technologies Inc.
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 101 U.S. patents, licenses or applications. This total includes 22 issued U.S. patents, 11 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com. Other investor-specific information about Biophan, including two streaming videos explaining some of the Company's patents and technology, can be found at links located at www.trilogy-capital.com.
Giant Motorsports Inc.
Giant Motorsports Inc., a high-growth public company in the expanding sports and recreational vehicle sector, is the nation's premier destination retailer for motorcycles, all-terrain-vehicles (ATVs), motor scooters and personal watercraft. Through implementation of a business strategy based on the highly efficient, regional "big-box" retailer model, Giant has become one of the largest multi-brand motorsports retailers in the United States. The Company leverages revenue and earnings growth through accretive acquisitions in new regions, and through consistent internal growth, and through utilization of rollup and consolidation strategies in the fragmented powersports national dealer environment. The Company possesses two wholly-owned subsidiaries, W.W. Cycles dba Andrews Cycles and Chicago Cycles. More information is located at http://www.andrewscycles.com, http://www.chicagocycle.com or www.trilogy-capital.com.
WorldWater & Power Corp.
WorldWater & Power Corp. is a full-service, international solar engineering and water management company with unique, high-powered and patented solar technology that provides solutions to a broad spectrum of the world's water supply and energy problems. The Company's recently patented AquaMax(TM) solar pumping systems are capable of driving motors up to 600 horsepower. For more information about WorldWater, visit the website at www.worldwater.com, or for investor-specific information, www.trilogy-capital.com.
About Trilogy Capital Partners
Trilogy Capital Partners is a Los Angeles-based financial services company engaged in merchant banking, strategic planning, financial marketing and communications. Based on the simple concept that many well-run public companies are not realizing their full value in the marketplace, Trilogy has aggregated highly experienced executives into a formidable financial and marketing team, which help investors identify and maximize prospective high-return opportunities. Trilogy is committed to identifying companies with strong management, a compelling business model and, most importantly, companies that may be seriously undervalued. For more information on Trilogy or its portfolio clients, please visit www.trilogy-capital.com.
Contact:
der laden/Klitsche ist mir zu blöd, echt!!!
und schon ausgegeben die Kohle?:-)))
p.s wärste mal bei Nuclear solution dabei gewesen!
das nenne ich Kohle machen!
Man konnte deutlich sehen das Bio nur für kurzzocks gut ist, für long kann man die beherzt einäschern (siehe chart)du Nix-schnaller!
Aber mach mal so weiter dann wirst du irgendwann zum Börsencrack, und was den Mitläufer anbelangt: Ich kenn nur einen der im Windschatten von z.B aida mitfährt und das bist du Kollege! Ausserdem wäre ich supergerne Mitläufer! schreib doch mal n' Buch wie man Mitläufer wird!
...die richtige Zeit zum Richtigen Zeitpunkt in der RICHTIGEN Firma investieren und das rechtzeitige Abspringen das lohnt!...aber wem sag ich das ?!?
wenn du das liest wirst selbst du begreifen das Aida mitläuft !
http://www.ariva.de/board/184839/thread.m?secu=156268@ANY
